Literature DB >> 24371621

Complete response with pegylated liposomal doxorubicin as a second-line therapy in metastatic ovarian carcinosarcoma: Significance of assessment of the response by FDG-PET.

C Gómez-Raposo1, M López-Gómez1, M Sereno1, F Zambrana1, E Casado1.   

Abstract

► We present a case report of a patient with an ovarian carcinosarcoma who achieve a complete response with PLD as a second-line therapy. ► There is little evidence regarding the effectiveness of second-line therapies in ovarian carcinosarcoma. ► Our case illustrates that the RECIST criteria is unreliable in predicting the histopathological treatment response in carcinosarcomas. ► FDG-PET was significantly more accurate than size-based criteria.

Entities:  

Keywords:  Chemotherapy; FDG-PET; Ovarian carcinosarcoma; Pegylated liposomal doxorubicin

Year:  2012        PMID： 24371621      PMCID： PMC3861262          DOI： 10.1016/j.gynor.2012.02.004

Source DB:  PubMed          Journal:  Gynecol Oncol Case Rep        ISSN： 2211-338X


  4 in total

1.  Adriamycin chemotherapy for malignant mixed mesodermal tumor of the ovary. A Gynecologic Oncology Group Study.

Authors:  C P Morrow; B N Bundy; J Hoffman; G Sutton; H Homesley
Journal:  Am J Clin Oncol       Date:  1986-02       Impact factor: 2.339

2.  A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study.

Authors:  G P Sutton; J A Blessing; H D Homesley; J H Malfetano
Journal:  Gynecol Oncol       Date:  1994-04       Impact factor: 5.482

3.  Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas.

Authors:  Vladimir Evilevitch; Wolfgang A Weber; William D Tap; Martin Allen-Auerbach; Kira Chow; Scott D Nelson; Fredrick R Eilber; Jeffery J Eckardt; Robert M Elashoff; Michael E Phelps; Johannes Czernin; Fritz C Eilber
Journal:  Clin Cancer Res       Date:  2008-02-01       Impact factor: 12.531

4.  Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.

Authors:  Irfan Cicin; Pinar Saip; Yesim Eralp; Meltem Selam; Samet Topuz; Yasemin Ozluk; Yucel Aydin; Erkan Topuz
Journal:  Gynecol Oncol       Date:  2007-10-23       Impact factor: 5.482
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.